Critical roles of the long noncoding RNA SNHG4 in human cancers.
- 1Department of Oncology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, 471000, Henan, China.
- 2Key Laboratory of Microecology-immune Regulatory Network and Related Diseases School of Basic Medicine, Jiamusi University, Jiamusi, 154007, Heilongjiang, China. [email protected].
Abstract
Cancer remains a major cause of morbidity and mortality worldwide, with its incidence and mortality rates continuing to rise. The long noncoding RNA SNHG4, a member of the small nucleolar RNA host gene family, has emerged as a candidate regulator in human cancers. This review synthesizes the currently reported expression patterns and clinical significance of SNHG4 across various malignancies, including colorectal cancer, hepatocellular carcinoma, gastric cancer, glioblastoma, prostate cancer, and lung cancer. Particular attention is given to tissue-dependent expression reversals, differences in evidence strength, and unresolved translational barriers. Additionally, this review describes the molecular mechanisms through which SNHG4 modulates oncogenic processes, including promoting cancer cell proliferation, migration, invasion, and epithelial‒mesenchymal transition and inhibiting apoptosis and ferroptosis. In summary, this review highlights the vital role of SNHG4 in cancer biology and critically evaluates its potential diagnostic and prognostic value together with the barriers to developing SNHG4-directed therapies. Despite these promising findings, the current evidence is largely derived from retrospective studies and preclinical models. Further large-scale, prospective multicenter studies with standardized detection methods are critically needed to validate the translational potential of SNHG4 before it can be considered for clinical application.
Related
- Deciphering the prognostic and immunological landscape of NFKBIA across human cancers
- GClnc1 as an emerging oncogenic regulator with mechanistic insights and clinical implications in human cancers
- Rac1 and CHK1 Converge on Abi-1 to Regulate DNA Repair Dependency and Treatment Response in Human Cancers
- Human Papillomavirus (HPV) Infection-Associated Epithelial-to-Mesenchymal Transition: Implication in Tumorigenesis and Pathogenesis of HPV-Positive Cancers
- Simulated Annealing Identifies Five Shared Drivers of T Cell Exhaustion Across Four Human Cancers
BibTeX
@article{ma2026critical,
title = {{Critical roles of the long noncoding RNA SNHG4 in human cancers.}},
author = {Yanpin Ma and Hairui Zhou},
journal = {Cell division},
year = {2026},
month = oct,
doi = {10.1186/s13008-026-00195-z},
url = {https://europepmc.org/article/MED/42963792},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Critical roles of the long noncoding RNA SNHG4 in human cancers.
AU - Yanpin Ma
AU - Hairui Zhou
PY - 2026
DA - 2026/10/14
JO - Cell division
DO - 10.1186/s13008-026-00195-z
UR - https://europepmc.org/article/MED/42963792
AB - Cancer remains a major cause of morbidity and mortality worldwide, with its incidence and mortality rates continuing to rise. The long noncoding RNA SNHG4, a member of the small nucleolar RNA host gene family, has emerged as a candidate regulator in human cancers. This review synthesizes the currently reported expression patterns and clinical significance of SNHG4 across various malignancies, including colorectal cancer, hepatocellular carcinoma, gastric cancer, glioblastoma, prostate cancer, and lung cancer. Particular attention is given to tissue-dependent expression reversals, differences in evidence strength, and unresolved translational barriers. Additionally, this review describes the molecular mechanisms through which SNHG4 modulates oncogenic processes, including promoting cancer cell proliferation, migration, invasion, and epithelial‒mesenchymal transition and inhibiting apoptosis and ferroptosis. In summary, this review highlights the vital role of SNHG4 in cancer biology and critically evaluates its potential diagnostic and prognostic value together with the barriers to developing SNHG4-directed therapies. Despite these promising findings, the current evidence is largely derived from retrospective studies and preclinical models. Further large-scale, prospective multicenter studies with standardized detection methods are critically needed to validate the translational potential of SNHG4 before it can be considered for clinical application.
SN - 1747-1028
ER -